DFV890
Symptomatic Knee Osteoarthritis
Key Facts
About IFM Therapeutics (2)
IFM Therapeutics is a pioneering biotech focused on modulating the innate immune system through first-in-class small molecules. It has demonstrated an exceptional track record of rapidly advancing programs from discovery to the clinic and securing major pharmaceutical partnerships and acquisitions, including multi-billion dollar deals with Bristol Myers Squibb and Novartis. The company's current lead asset, DFV890 (formerly IFM-2427), is a NLRP3 antagonist in multiple Phase 2 trials across inflammatory and hematologic indications. Its innovative 'IFM Model' of subsidiary creation allows for focused R&D and capital-efficient value realization.
View full company profileAbout IFM Therapeutics (2)
IFM Therapeutics is a pioneering biotech focused on modulating the innate immune system through first-in-class small molecules. It has demonstrated an exceptional track record of rapidly advancing programs from discovery to the clinic and securing major pharmaceutical partnerships and acquisitions, including multi-billion dollar deals with Bristol Myers Squibb and Novartis. The company's current lead asset, DFV890 (formerly IFM-2427), is a NLRP3 antagonist in multiple Phase 2 trials across inflammatory and hematologic indications. Its innovative 'IFM Model' of subsidiary creation allows for focused R&D and capital-efficient value realization.
View full company profileAbout IFM Therapeutics (2)
IFM Therapeutics is a pioneering biotech focused on modulating the innate immune system through first-in-class small molecules. It has demonstrated an exceptional track record of rapidly advancing programs from discovery to the clinic and securing major pharmaceutical partnerships and acquisitions, including multi-billion dollar deals with Bristol Myers Squibb and Novartis. The company's current lead asset, DFV890 (formerly IFM-2427), is a NLRP3 antagonist in multiple Phase 2 trials across inflammatory and hematologic indications. Its innovative 'IFM Model' of subsidiary creation allows for focused R&D and capital-efficient value realization.
View full company profileAbout IFM Therapeutics (2)
IFM Therapeutics is a pioneering biotech focused on modulating the innate immune system through first-in-class small molecules. It has demonstrated an exceptional track record of rapidly advancing programs from discovery to the clinic and securing major pharmaceutical partnerships and acquisitions, including multi-billion dollar deals with Bristol Myers Squibb and Novartis. The company's current lead asset, DFV890 (formerly IFM-2427), is a NLRP3 antagonist in multiple Phase 2 trials across inflammatory and hematologic indications. Its innovative 'IFM Model' of subsidiary creation allows for focused R&D and capital-efficient value realization.
View full company profile